Peter Hillmen is Professor of Hematology and Honorary Consultant Hematologist at Leeds Teaching Hospitals NHS Trust – www.leedsth.nhs.uk
Prof. Hillmen qualified in Medicine at Leeds Medical School in 1985 and completed his general medical training in Leeds in 1988. He was appointed Professor of Hematology at the University of Leeds in 2013.
Prof. Hillmen has research interests in both paroxysmal nocturnal haemoglobinuria (PNH) and chronic lymphocytic leukemia (CLL). His research into PNH, which he has conducted since 1990, eventually led to the development of anti-complement therapy for the disease. Furthermore, he was the lead on the trials of eculizumab and is currently leading the National PNH Service based in Leeds and Kings.
Understanding the pathophysiology of and developing novel therapies for CLL, has been an interest of his since 1995. His group pioneered the use of minimal residual disease assessment in CLL and his research now focuses on the mechanism of action of targeted therapies with the aim of maximizing their potential. He also chairs the NCRI CLL sub-group in the UK, which is responsible for the development of UK CLL Clinical Trials.
By choosing to continue, you are confirming that you are a healthcare professional